Matthew Rizzo is Director & 10% Owner at Xtant Medical Holdings, Inc. (XTNT). They have made 1 open-market trade across 1 company since 2018, most recently 2022-08-15.
CIK 0001732511
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $13.6M since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XTNT | 215,415 | $61K |
Shares reported on the most recent Form 4, priced at the 2022-08-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XTNT | BUY | 2018-02-14 | 2018-02-26 | $7.20 | $13.6M | -9.9% | +6.0% | -14.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.